PHARMACOKIN ETICS OF INFIGRATINIB AND ITS ACTIVE METABOLITES IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA HARBORING FGFR2 GENE AMPLIFICATIONS.

被引：0
|
作者：
Yuan, J. [1 ]
Shen, L. [1 ]
Liu, T. [2 ]
Xu, H. [3 ]
Yang, J. [4 ]
Wei, J. [5 ]
Jiang, H. [6 ]
Deng, Y. [7 ]
Wang, Y. [8 ]
Zhang, X. [1 ]
Gong, J. [1 ]
Lyu, C. [9 ]
Zhang, L. [9 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[3] Hubei Canc Hosp, Wuhan, Peoples R China
[4] Fujian Canc Prov Canc Hosp, Fujian, Peoples R China
[5] Nanjing Univ, Med Sch, 5Nanjing Drum Tower Hosp, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong, Peoples R China
[8] Shanxi Canc Hosp, Taiyuan, Peoples R China
[9] Shanghai LianBio Dev Co, Shanghai, Peoples R China
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-134
引用
收藏
页码：S93 / S93
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
    Yuan, J.
    Shen, L.
    Liu, T.
    Xu, H.
    Yang, J.
    Wei, J.
    Jiang, H.
    Deng, Y.
    Wang, Y.
    Zhang, X.
    Gong, J.
    Lyu, C.
    Li, Y.
    Song, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S859 - S860
  • [2] Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification
    Yuan, Jiajia
    Shen, Lin
    Liu, Tian Shu
    Xu, Huiting
    Yang, Jianwei
    Wei, Jia
    Jiang, Haiping
    Deng, Yanhong
    Pan, Hongming
    Wang, Yusheng
    Zhang, Xiaotian
    Peng, Zhi
    Qi, Changsong
    Zhang, Lingli
    Hsu, Peiwen
    Song, Lin
    Mu, Lei
    Sun, Qiao
    Gong, Jifang
    Lyu, Cheng
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (12):
  • [3] Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications
    Satoh, Taroh
    Barthelemy, Philippe
    Nogova, Lucia
    Honda, Kazunori
    Hirano, Hidekazu
    Lee, Keun-Wook
    Rha, Sun Young
    Ryu, Min-Hee
    Park, Joon Oh
    Doi, Toshihiko
    Ajani, Jaffer
    Hangai, Nanae
    Kremer, Jill
    Mina, Mark
    Liu, Mei
    Shitara, Kohei
    EUROPEAN JOURNAL OF CANCER, 2025, 218
  • [4] Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements
    White, Kathryn
    Anwar, Ahmed I.
    Jin, Kevin
    Bollich, Victoria
    Kelkar, Rucha A.
    Talbot, Norris C.
    Klapper, Rachel J.
    Ahmadzadeh, Shahab
    Viswanath, Omar
    Varrassi, Giustino
    Shekoohi, Sahar
    Kaye, Alan D.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [5] POPULATION PHARMACOKIN ETICS AND EXPOSURE-RESPONSE ANALYSES OF ZOLBETUXIMAB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROES OPHAGEAL JUNCTION ADENOCARCINOMA
    Yamada, A.
    Takeuchi, M.
    Komatsu, K.
    Bonate, P.
    Poondru, S.
    Yang, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
  • [6] Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
    Satoh, T.
    Barthelemy, P.
    Nogova, L.
    Honda, K.
    Iwasa, S.
    Lee, K.
    Rha, S.
    Ajani, J.
    Hangai, N.
    Liu, S.
    Kremer, J.
    Mina, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S165 - S166
  • [7] Impact on work productivity in unresectable locally advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma patients and their caregivers
    Xiao, H.
    Hall, J. P.
    Khela, K.
    Moon, R.
    Bertwistle, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S904 - S904
  • [8] Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
    Peng, Zhi
    Li, Zhongwu
    Gao, Jing
    Lu, Ming
    Gong, Jifang
    Tang, En-Tzu
    Oliner, Kelly S.
    Hei, Yong-Jiang
    Zhou, Hui
    Shen, Lin
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (11) : 2634 - 2641
  • [9] Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Shitara, Kohei
    Xu, Rui-Hua
    Ajani, Jaffer A.
    Moran, Diarmuid
    Guerrero, Abraham
    Li, Ran
    Pavese, Janet
    Matsangou, Maria
    Bhattacharya, Pranob
    Ueno, Yoko
    Wang, Xuewei
    Shah, Manish A.
    GASTRIC CANCER, 2024, 27 (05) : 1058 - 1068
  • [10] The prognostic impact of FGFR2 gene amplification in patients receiving fluoropyrimidine and platinum (FP) chemotherapy for with metastatic and locally advanced gastric cancers
    Seo, S.
    Park, S. J.
    Park, S. R.
    Ryu, M. H.
    Ryoo, B. Y.
    Park, Y. S.
    Na, Y. S.
    Lee, C. W.
    Lee, J. K.
    Kang, Y. K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S472 - S472
12345